I chat with the CEO of a company that is perfecting the technology to make viable organ replacements a safe, accessible, and affordable reality.  Heart disease is the #1 cause of death in virtually all developed countries throughout the world, but one company looking to change the way we treat heart disease is BIOLIFE4D. Based out of Chicago, BIOLIFE4D is a pioneering biotech company laser-focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. Operated by seasoned business leaders and guided by world-class biomedical engineers and life sciences experts, BIOLIFE4D is driving a movement to transform the treatment of heart disease. I wanted to learn more about how they are perfecting the technology to make viable organ replacements a safe, accessible, and affordable reality. While leading CMCS, Steven simultaneously conducted more than two years of in-depth research into the specific processes and technologies of the 3D bioprinting and regenerative medicine field – and quickly recognized the nearly unlimited financial and human potential of this emerging market. Coupling his vast hands-on experience in medical manufacturing with extensive research and a partnership with industry-leading experts he formed BIOLIFE4D, a regenerative medicine 3D bioprinting company with the goal of facilitating the biological printing of viable human organs for utilization in patient-specific human transplantation. Steven Morris joins me on Tech Talks Daily to talk about their recent milestone, the benefits of printing a mini heart, and how bioprinting can revolutionize healthcare, and this is the closest anyone's ever gotten.